# China NMPA Inspection - Guilin Pharmaceutical Co., Ltd. - May 31, 2015

Source: https://www.globalkeysolutions.net/records/china_inspection/guilin-pharmaceutical-co-ltd/11ce200c-1831-4eec-8040-a09e8803dca9
Source feed: China

> China NMPA unannounced inspection for Guilin Pharmaceutical Co., Ltd. published May 31, 2015. A regulatory announcement initiated an investigation into pharmaceutical manufacturers purchasing unauthorized ginkgo leaf extract from Guilin Xingda 

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Report on the on-site inspection of four companies, including Heilongjiang Tianhong Pharmaceutical Co., Ltd.
- Company Name: Guilin Pharmaceutical Co., Ltd.
- Publication Date: 2015-05-31
- Product Type: Drugs
- Summary: A regulatory announcement initiated an investigation into pharmaceutical manufacturers purchasing unauthorized ginkgo leaf extract from Guilin Xingda Pharmaceutical Co., Ltd. The inquiry revealed that 19 companies, including Zhuozhou Dongle Pharmaceutical Co., Ltd., used this extract in drug production. These companies subsequently ceased operations, halted sales, and recalled affected products.

Further provincial inspections identified additional cases. Heilongjiang Tianhong Pharmaceutical Co., Ltd. (inspected May 20) purchased extract but did not use it due to failed incoming inspections, sealing the material. Shandong Luxi Pharmaceutical Co., Ltd. (inspected May 21-22) had an employee acquire a small quantity for personal, non-production use. Chengdu Senke Pharmaceutical Co., Ltd. (inspected May 26) purchased a small amount for research and development, not drug manufacturing.

A significant violation was found at Wuhan Mingshi Biomedical Technology Co., Ltd. (inspected May 22 and 27). Lacking pharmaceutical production qualifications, the company purchased multiple batches of the unauthorized extract from July 2014 to April 2015. It then used this material to produce "Mingshi Brand Jinxinbao Capsules," a health food product. Three batches of these capsules were sold, while a fourth remained unsold. In response, regulatory authorities seized all raw materials and finished products, and the company ceased production, sales, and initiated product recalls, underscoring stringent enforcement against unauthorized ingredients in both pharmaceutical and health food sectors.

Company: https://www.globalkeysolutions.net/companies/guilin-pharmaceutical-co-ltd/8a53776f-b81a-417d-b1c5-ea1cd2d0b0a8